Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. reported that Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, and President and CEO of Lillibridge Healthcare Services, Inc., is expected to retire effective May 1, 2026. He will remain in his current roles until that date, giving the company time to run a comprehensive search for his replacement. The advance notice is also intended to support an orderly transition of responsibilities to his successor. The company issued a press release on November 17, 2025, to formally announce his planned retirement.
Ventas, Inc. filed a Form 13F reporting its institutional holdings with a Form 13F Information Table value total of $123,788,138. The report lists 1 information table entry, indicates 0 other included managers, and was signed by Carey S. Roberts on 11-14-2025.
Ventas (VTR) Form 4: EVP & CFO Robert F. Probst exercised stock options for 33,591 shares at $73.71 on 11/12/2025 and sold 33,591 shares at a weighted average price of $76.7719, pursuant to a Rule 10b5-1 trading plan entered on February 19, 2025.
The options were fully vested, scheduled to expire within the next nine months, and relate to an award first exercisable on 08/03/2016 with an expiration date of 08/03/2026. Following the transactions, Probst directly beneficially owns 168,364 shares. The sale occurred across multiple trades at prices ranging from $76.71 to $76.9376.
VTR: A Form 144 notice discloses a proposed sale of up to 33,591 shares of common stock through Merrill Private Wealth, with an aggregate market value of 2,578,846.3. The approximate sale date is 11/12/2025 on the NYSE. The shares were acquired on 11/12/2025 via an exercise of employee stock options from the issuer using a broker-assisted cashless exercise.
Shares outstanding were 469,732,824; this is a baseline figure, not the amount being offered.
Ventas, Inc. (VTR) disclosed a Form 4 for officer Peter J. Bulgarelli, who sold 40 shares of common stock on 11/07/2025 at a $75.7013 weighted average, with trades ranging from $75.26 to $76.14. The transaction was executed under a Rule 10b5-1 trading plan entered on February 20, 2025.
Following the sale, Bulgarelli beneficially owns 111,488 shares, held directly.
Ventas, Inc. (VTR) received a Form 144 notice for a proposed sale of common stock. The notice covers 40 shares with an aggregate market value of $3,028.05, to be executed through Northern Trust Securities, Inc. The approximate sale date is 11/07/2025 on the NYSE.
The shares were acquired as compensation on 02/01/2023. The filing also lists recent transactions by the same seller over the past three months, including sales on 09/15/2025 (406 shares; $28,418.94), 09/30/2025 (2,040; $142,779.60), 10/01/2025 (2,554; $179,435.36), 11/04/2025 (3,924; $294,286.66), 11/05/2025 (870; $65,493.95), and 11/06/2025 (166; $12,475.48).
Ventas, Inc. (VTR) reported insider stock sales by Executive Vice President (EVP OM&R-Ventas/Pres&CEO-LHS) Peter J. Bulgarelli. The transactions were open‑market sales coded “S” and executed under a Rule 10b5‑1 trading plan entered on February 20, 2025.
He sold 3,924 shares on 11/04/2025 at a weighted average price of $74.9966 (range $74.99–$75.11), 870 shares on 11/05/2025 at $75.2804 (range $74.99–$75.5623), and 166 shares on 11/06/2025 at $75.1535 (range $75.01–$75.39). Following these transactions, he beneficially owns 111,528 shares, held directly.
Ventas (VTR) reported insider transactions by Chairman and CEO Debra A. Cafaro. On 11/04–11/06/2025, she exercised options at $63.24 for 11,452, 19,250, and 264 shares, then sold equal shares at weighted average prices of $75.0216, $75.2908, and $75.0489, pursuant to a Rule 10b5-1 plan entered on March 28, 2024. The options exercised were fully vested and scheduled to expire within the next 12 months. Following these trades, she directly owns 1,145,695 common shares and holds 82,582 unexercised options expiring on 11/02/2026.
Ventas, Inc. (VTR) received a Form 144 notice indicating an intended sale of 166 shares of common stock, with an aggregate market value $12,475.48. The proposed sale is listed through Northern Trust Securities, Inc. on or about 11/06/2025, and the shares trade on the NYSE. The seller acquired the shares on 02/01/2023 as compensation shares. Shares outstanding were 469,732,824.
Recent sales by the same seller include 406 shares for $28,418.94 on 09/15/2025 and 2,040 shares for $142,779.60 on 09/30/2025.
Ventas, Inc. (VTR) reported a Form 144 notice for a planned sale of 264 shares of common stock by Debra Cafaro. The filing lists an aggregate market value of $19,812.92, with an approximate sale date of 11/06/2025, to be executed through Merrill Lynch on the NYSE. The shares to be sold were acquired on 11/06/2025 via a broker-assisted exercise of employee stock options.
Recent activity disclosed includes prior sales over the past three months, such as 317,258 shares on 10/30/2025 for $23,554,765.13 and 219,515 shares on 10/20/2025 for $15,656,406.48. Shares outstanding were 469,732,824; this is a baseline figure, not the amount being sold.